Get Permission Patel and Choraria: Epidemiological fectors and antibiotic susceptibility pattern of Salmonella spp


Introduction

Salmonella infections are a big public health concern around the world. Antibiotic resistance and multi resistance of Salmonella spp. have developed dramatically in the recent decade, particularly in poor countries, as a result of increased and indiscriminate antibiotic usage in the treatment of humans and animals. Annually, it is predicted that 22 million new cases of enteric fever are diagnosed. South Central Asia and Southeast Asia have the highest rates of enteric fever (> 100 cases per 100,000 people per year). Except for Australia and New Zealand, the rest of Asia, Africa, Latin America, the Caribbean, and Oceania have a moderate incidence (10-100 cases per 100,000 people per year).1

In poor countries, such as India, enteric fever is a major public health issue. In areas with poor hygiene and sanitation, many human-restricted diseases are spread by the faecal channel, resulting in high morbidity and mortality. Appropriate antimicrobial therapy can help to minimise the disease's morbidity and mortality. Antibiotic therapy is the cornerstone of enteric fever treatment, with fatality rates as high as 30% in untreated patients and as low as 1% with proper antibiotic therapy. Enteric fever is caused by Salmonella enteric serovar Typhi and Paratyphi A, which are the most common etiological agents in India, especially during the summer.2

Since 1960, multidrug-resistant S. Typhi has been observed, resistant to all three antityphoidal antimicrobial agents: ampicillin, chloramphenicol, and cotrimoxazole.3 The first epidemic of multidrug-resistant S. Typhi (MDRST) was recorded in Calicut.4

Materials and Methods

Salmonella isolates obtained from blood cultures received for routine bacterial culture sensitivity at the microbiology laboratory between January 2015 and September 2017 were included in the study. The study protocol was approved by the hospital ethics committee. A retrospective analysis of laboratory records was carried out over these 3 years. Only one isolate per patient was included. All the blood culture samples were processed by the automated blood culture system‑BACTEC 9030 (Becton Dickinson). Collection of blood, incubation, and subcultures onto blood agar and Mac-Conkey agar were done as per the standard methods. Suspected non-lactose-fermenting colonies were further processed and identified by biochemical reactions.

Antibiotic susceptibility was performed using the Kirby‑Bauer disk diffusion method according to Clinical and Laboratory Standards Institute (CLSI) guidelines for the corresponding years using commercially available disks (Hi‑media Laboratories, India) of ampicillin (10 μg), chloramphenicol (30 μg), co‑trimoxazole (1.25/23.75 μg), ciprofloxacin (5 μg), cefotaxime (30 μg) and nalidixic acid (NA) (30 μg). Escherichia coli ATCC 25922 was used as the quality control strain. Isolates with intermediate levels of resistance in disk diffusion were included in the percentage of resistant organisms for final analysis.

Result

From the year January 2015 to September 2017 total 330 blood culture is positive for Salmonella spp. Out of that total 298 are Salmonella typhi while 32 Salmonella. Paratyphi A which is almost 10% of total.

Figure 1

Age wise distribution of cases (graff 1)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/c6da1520-13cc-44fe-9c5b-808a5f5fdaa7image1.png

All age group and both sexes are involved. The mean age is 15 years. The male to female ratio was 1.9:1 (graff 1).

Figure 2

Month-wise distribution of cases (graff 2)

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/c6da1520-13cc-44fe-9c5b-808a5f5fdaa7image2.png

The peek months are April, May, June and July according to our study (graff 2). S. typhi was most susceptible towards cefotaxime (99%), followed by chloramphenicol (90%), Co-trimoxazol (89%), ampicilline (86%), Ciprofloxacin (36%) &Nalidixic acid (20%) (Table 1).

In case of S. paratyphi Amost of the tested antibiotics showed high percentage of susceptibility and the least susceptible antibiotic was Nalidixic acid (16%) followed by Ciprofloxacin (31%) (Table 2).

Out of the 298 S.typhi isolates; 10(3%) isolates were multidrug resistance, showing resistance simultaneous to Ampicillin, Chloramphinicol, and Co-trimoxazole which are first line anti typhoidaldrugs. While considering Nalidixic acid resistant Salmonella(NARS) total 236 S.typhi which is 79% of total S.typhi are NARS, While 25 which is 78% out total S.para A are NARS.

Table 1

Number of sensitive S.TYPHI

2015(85)

2016(160)

2017(53)

Total(298)

AMP

83

127

47

257 (86%)

CTX

85

160

52

297(99%)

CIP

38

51

18

107(36%)

COT

84

132

48

264(89%)

C

82

138

49

269(90%)

NA

34

12

14

60(20%)

Table 2

Number of sensitive S.TYPHI PARA A

2015(5)

2016(10)

2017(17)

Total(32)

AMP

5

10

17

32(100%)

CTX

5

10

17

32(100%)

CIP

4

3

3

10(31%)

COT

5

10

17

32(100%)

C

5

10

17

32(100%)

NA

2

0

3

5(16%)

Table 3

Comparission of different study with our study

Antibiotics (% of Sensitive)

Joshi BG et al 2011 5

Gordana Mijovic et al 2012 6

Ashwini Choudhary et al 2013 7

In our study, Jan 2015- Sept 2017

Ampicillin (Amp)

76

92

91

86

Cefotaxim (CTX)

100

98

100

99

Ciprofloxacin (CIP)

88

98

54

36

Co-trimoxazole (COT)

100

96

95

89

Chloremphenicl (C)

100

98

100

90

Nalidixic acid (NA)

44

83

8

20

Discussion

In our study 1yr till 30 yrs., age groups are involved with mean age of occurrence is 15yrs. This can be correlated with L Singhal et al studies shows8 more patient belongs to pediatric age group (< 12 yrs). Contratery to that Raza S et al studies9 shows most of the positive cases lie in the age group 21-40 years.

The seasonal trend of typhoid fever in our study starts from April, May, June and July. which is been co-relate with L Singhal et al9 study showing peaked during July‑September (rainy seasons) followed by April‑June each year.Similar observation is made with Joshi BG5 study showing the occurrence of the disease was higher during summer and rainy season.

If we compare the antibiotic susceptibility of Salmonella typhi in our study and other studies, it will show you the following results (Table 3).

In our study Salmonella paratyphiA shows 100% susceptibility to ampiciin, cefotaximco-trimxazole & Chloremphenicol. While ciprofloxacin is 31% sensitive and Nalidixic acid is 16% sensitive. Similar results are seen with other studies, Joshi BG et al 2011.5 shows 100% sensitivity towards ciprofloxacin, co-trimoxazole and chloramphenicol, while ampicillin is 26% sensitive.

In our study total 261(79%) of salmonella isolates are NARS. Nalidixic acid resistance screening is not a reliable surrogate indicator of ciprofloxacin resistance. Ciprofloxacin MIC should to beroutinely done. While multi drug resistant salmonella are 10(3%), while study with Gordana Mijovic 20126 shows 1.8% MDR in theire 2 survey comparision study, while Raza S et al8 study shows 3 isolates out of 47 showing multi drug resistance. Kavita Nagshetty 201010 et al’s study shows total 9(10%) MDR isolates. Carbapenems are the antibiotic of choice for organisms showing MDR. In our study imipenem & meropenem are 100% sensitive. Also azithromycin shows 100% sensitivity.

Conclusion

In conclusion, Sensitivity pattern of the Salmonella isolates are ever changing. In our study maximum isolates are Salmonella typhi followed by Salmonella para A and only one isolate is of Salmonella para B. Sensitivity to first line anti-typhoidal drugs are >80%. while sensitivity to Nalidixic acid is 20% only and to ciprofloxacin is 36%. Also increasing resistance to Nalidixixc acid and there by to quinolones is alarming and of particular concern to do MIC levels for ciprofloxacin. Multi-drug resistant salmonella are 10(3%) in three year span, but definitely indicating the up- surgence of MDR strain in Surat. While all carbapenem and Azithromycin are 100% sensitive. Which are the alternative mode of treatment of MDR isolates.

Conflict of Interest

The authors declare that there are no conflicts of interest in this paper.

Source of Funding

None.

References

1 

A Maharjan B Dhungel A Bastola UT Shrestha N Adhikari MR Banjara Binod Dhungel et al Antimicrobial Susceptibility Pattern of Salmonella spp. Isolated from Enteric Fever Patients in Nepal InfectInfect Dis Rep20211338840010.3390/idr13020037

2 

L Singhal Gupta Trends in antimicrobial susceptibility of Salmonella Typhi from North India (2001-2012)Indian J Med Microbiol200132214952

3 

D Acharya Antibiotic Susceptibility Pattern and the Indicator of Decreased Ciprofloxacin Susceptibility of Salmonella enteric SerovarTyphi Isolated from Dhulikhel HospitalJpn J Infect Dis20126532647

4 

SC Agarwal Chloramphenicol resistance of Salmonella species in IndiaBull World Health Organ19622733315

5 

G Mijović B Andrić D Terzić M Lopičić B Dupanović Antibiotic susceptibility of salmonella spp.: a comparison of two surveys witha 5 years intervalJ IMAB - Annual Proceeding (Scientific Papers)20121812169

6 

B G Joshi K Keyal R Pandey BM Shrestha Clinical Profile and Sensitivity Pattern of Salmonella Serotypes in Children: A Hospital Based StudyJ Nepal Paediatric Soc2011313180310.3126/jnps.v31i3.4382

7 

A Choudhary R Gopalakrishnan PS Nambi V Ramasubramanian KA Ghafur MAT Affiliations Antimicrobial susceptibility of Salmonella enterica serovars in a tertiary care hospital in southern IndiaIndian J Med Res201313748002

8 

L Singhal Trends in antimicrobial susceptibility of Salmonella Typhi from North India (2001‑2012Indian J Med Microbiol200132214952

9 

S Raza Antimicrobial Susceptibility Patterns of Salmonellatyphiand Salmonella paratyphi A in a TertiaryCare HospitalJ Nepal Health Res Counc201210222147

10 

K Nagshetty ST Channappa SM Gaddad Antimicrobial susceptibility of Salmonella Typhi in India ,KavitaNagshettyJ Infect Dev Ctries20104270310.3855/jidc.109



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 15-06-2021

Accepted : 04-08-2021


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/ 10.18231/j.ijmmtd.2021.030


Article Metrics






Article Access statistics

Viewed: 731

PDF Downloaded: 329